Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Urinary Biomarker Found for Prostate Cancer Risk

By LabMedica International staff writers
Posted on 02 Nov 2010
A protein in urine could be a reliable marker for prostate cancer assessment and has advantages over the standard prostate specific antigen (PSA) test. More...


The protein, microseminoprotein-beta (MSMB), which is produced by normal prostate cells and secreted into urine from semen, regulates cell apoptosis or programmed cell death and is linked to an increased risk of developing prostate cancer.

In a multi-institute collaborative study, led by scientists from the Institute of Cancer Research, (CRUK; Cambridge, UK), tissue, urine and blood samples were analyzed from cohorts of prostate cancer patients. Urinary PSA and MSMB levels were determined by enzyme-linked immunoassays (ELISA) and normalized to creatinine. Samples from 133 of the patients were made into a tissue microarrays (TMA) containing multiple cores from normal/benign regions (>3), prostatic intraepithelial neoplasia (PIN) and at least two distinct regions of tumor for each patient. Genotyping was performed on DNA extracted from blood samples.

The urinary levels of MSMB were determined in 215 men with no history of prostate disease and 89 men with prostate cancer. Consistent with the association in prostate tissue there was a significant decrease in urinary MSMB in men with tumors compared with men with no history of prostate disease. No normal or tumorigenic tissues demonstrated any MSMB staining suggesting that at the protein level in tissue MSMB is highly prostate specific. In particular the tissues surrounding the prostate, such as urothelium, seminal vesicles and bladder muscularis propria layer showed no staining whereas adjacent benign prostate glands were heavily stained. MSMB demonstrated high levels of specificity and sensitivity particularly when compared to urinary PSA. There was a significant decrease in urinary MSMB with the high risk allele compared to the low risk allele.

Hayley Whitaker, Ph.D., the lead author, said, "Microseminoprotein-beta (MSMB), is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk". The study was published on line on October 13, 2010, in the open access journal from the Public Library of Science, PLoS One.

Related Links:
Institute of Cancer Research



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.